September 4, 2015 | Authors of a new paper in
JAMA Oncology argue that universal testing for breast cancer-related BRCA mutations offers vanishingly low benefit for the cost — but with several providers finding ways to offer these tests for just a few hundred dollars, that calculation may quickly be due for a revision.
MedPage Today